Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy
Signals new era for cancer treatment
SAN DIEGO--(BUSINESS WIRE)--#biotech--Immunicom, Inc., a global biotech company that is redefining immuno-oncology with breakthrough non-pharmaceutical subtractive immunotherapy treatments designed to preserve quality-of-life while being treated, presented preliminary data from its late-stage, metastatic triple-negative breast cancer (mTNBC) clinical trial at the American Association of Cancer Research (AACR) Annual Meeting 2021. AACR’s Annual Meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers, attracting more than 20,000 participants annually.
Immunicom is investigating its FDA-designated breakthrough Immunopheresis™ therapy, which is a filtration-based subtractive treatment designed to capture sTNF-R proteins that are shed by cancer cells and inhibit a patient’s natural anti-tumor immune activity. Immunicom presented data for the first cohort of mTNBC patients treated with Immunopheresis which showed an 80% decrease of the inhibitory sTNF-R proteins and observed a sustained quality-of-life while on therapy with minimal side effects.
“Current cancer treatments have significant toxicities and can dramatically diminish a patient’s quality-of-life, especially in patients with late-stage disease that have received multiple prior courses of therapy,” said Amir Jafri, Immunicom CEO and Founder. “We are studying an innovative emerging therapy which could signal a new era for cancer treatment that employs a novel immunotherapeutic approach which is especially well-tolerated by these fragile patients.”
Immunicom’s presentation “Extracorporeal pulldown of soluble TNFRs to unleash the activity of endogenous TNFα in chemorefractory triple-negative breast cancer patients - first-in-human experience” was presented by the study’s Chief Investigator, Piotr Wysocki, MD, PhD, Department Head of Oncology at the Jagiellonian University – Medical College Hospital in Krakow and President of the Polish Society of Clinical Oncology, and will be available online until June 21, 2021, details as follows:
Immunicom, Inc. creates novel immunotherapies designed to treat a variety of diseases using its breakthrough Immunopheresis™ technology platform to improve patient access and affordability. The privately held medical technology company develops innovative, non-pharmaceutical approaches for treating cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom’s revolutionary blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, with possibly fewer side effects. Immunicom’s lead product, the LW-02 column, has received U.S. FDA Breakthrough Device designation for stage IV metastatic cancer and European regulatory clearance (CE Mark certification) for use in adults with advanced, refractory, triple negative breast cancer (TNBC). Immunopheresis is currently being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Philadelphia, PA, Houston, TX, and Krakow, Poland.
Forward Looking Statements
This press release contains certain forward-looking statements regarding Immunicom device capabilities. All such statements are based upon current Immunicom expectations and involve a number of business and technical risks and uncertainties that could cause actual results to differ materially from anticipated results described, implied or projected in any forward-looking statement, including, without limitation, clinical trial results, regulatory approvals, unexpected changes in technologies, uncertainties inherent in product development and commercialization, intellectual property protection, and the ability of our products to gain market acceptance.